PHAXIAM Therapeutics S.A. (0QSS.L)
EUR 1.76
(1.03%)
EUR 1.76
(1.03%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -23.66 Million EUR | 26.25% |
| 2022 | -32.08 Million EUR | 47.14% |
| 2021 | -60.69 Million EUR | 16.34% |
| 2020 | -72.55 Million EUR | -4.6% |
| 2019 | -69.35 Million EUR | -44.29% |
| 2018 | -48.06 Million EUR | -40.33% |
| 2017 | -34.25 Million EUR | -30.69% |
| 2016 | -26.21 Million EUR | -42.21% |
| 2015 | -18.43 Million EUR | -105.98% |
| 2014 | -8.94 Million EUR | -25.8% |
| 2013 | -7.11 Million EUR | -513.35% |
| 2012 | -1.15 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -5.32 Million EUR | -215.14% |
| 2024 Q2 | -5.32 Million EUR | 0.0% |
| 2023 Q2 | -12.67 Million EUR | -182.16% |
| 2023 FY | -25.41 Million EUR | 20.78% |
| 2023 Q3 | -9.17 Million EUR | 27.65% |
| 2023 Q4 | -1.69 Million EUR | 81.56% |
| 2023 Q1 | -4.49 Million EUR | 47.66% |
| 2022 Q3 | -5.56 Million EUR | 77.92% |
| 2022 FY | -32.08 Million EUR | 47.14% |
| 2022 Q4 | -8.58 Million EUR | -54.2% |
| 2022 Q2 | -25.21 Million EUR | -101.45% |
| 2022 Q1 | -12.51 Million EUR | 57.52% |
| 2021 Q3 | -14.6 Million EUR | 53.25% |
| 2021 FY | -60.69 Million EUR | 16.34% |
| 2021 Q4 | -29.45 Million EUR | -101.75% |
| 2021 Q1 | -13.24 Million EUR | 62.51% |
| 2021 Q2 | -31.23 Million EUR | -135.83% |
| 2020 Q4 | -35.33 Million EUR | -119.06% |
| 2020 FY | -72.55 Million EUR | -4.6% |
| 2020 Q1 | -19.09 Million EUR | 47.18% |
| 2020 Q2 | -37.21 Million EUR | -94.95% |
| 2020 Q3 | -16.12 Million EUR | 56.66% |
| 2019 Q1 | -13.26 Million EUR | -32.7% |
| 2019 Q2 | -33.21 Million EUR | -150.4% |
| 2019 FY | -69.35 Million EUR | -44.29% |
| 2019 Q4 | -36.14 Million EUR | -117.84% |
| 2019 Q3 | -16.59 Million EUR | 50.04% |
| 2018 Q4 | -9.99 Million EUR | 14.91% |
| 2018 Q3 | -11.74 Million EUR | 6.93% |
| 2018 Q2 | -12.62 Million EUR | -36.29% |
| 2018 Q1 | -9.26 Million EUR | 5.62% |
| 2018 FY | -48.06 Million EUR | -40.33% |
| 2017 Q4 | -9.81 Million EUR | -42.39% |
| 2017 Q1 | -6.53 Million EUR | -10.97% |
| 2017 Q2 | -7.65 Million EUR | -17.26% |
| 2017 FY | -34.25 Million EUR | -30.69% |
| 2017 Q3 | -6.89 Million EUR | 10.03% |
| 2016 Q2 | -6.19 Million EUR | -39.87% |
| 2016 Q4 | -5.88 Million EUR | 0.0% |
| 2016 Q3 | -5.88 Million EUR | 4.95% |
| 2016 FY | -26.21 Million EUR | -42.21% |
| 2016 Q1 | -4.42 Million EUR | -1.55% |
| 2015 Q4 | -4.35 Million EUR | 0.0% |
| 2015 Q3 | -4.35 Million EUR | -27.03% |
| 2015 FY | -18.43 Million EUR | -105.98% |
| 2015 Q2 | -3.43 Million EUR | 0.0% |
| 2015 Q1 | -3.43 Million EUR | -19.07% |
| 2014 Q4 | -2.88 Million EUR | 0.0% |
| 2014 Q1 | -1.59 Million EUR | 23.74% |
| 2014 Q3 | -2.88 Million EUR | -81.08% |
| 2014 Q2 | -1.59 Million EUR | 0.0% |
| 2014 FY | -8.94 Million EUR | -25.8% |
| 2013 FY | -7.11 Million EUR | -513.35% |
| 2013 Q2 | -1.46 Million EUR | 0.0% |
| 2013 Q3 | -2.08 Million EUR | -42.04% |
| 2013 Q1 | -1.46 Million EUR | -255.71% |
| 2013 Q4 | -2.08 Million EUR | 0.0% |
| 2012 Q4 | 943.65 Thousand EUR | 0.0% |
| 2012 FY | -1.15 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Boiron SA | 42.29 Million EUR | 155.947% |
| Laboratorios Farmaceuticos Rovi, S.A. | 220.25 Million EUR | 110.742% |
| Vetoquinol SA | 74.26 Million EUR | 131.859% |
| Valneva SE | -82.08 Million EUR | 71.177% |
| AB Science S.A. | -13.42 Million EUR | -76.186% |
| Nanobiotix S.A. | -26.77 Million EUR | 11.647% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 17.953% |
| BioSenic S.A. | -7.04 Million EUR | -236.08% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 81.425% |
| Formycon AG | -369 Thousand EUR | -6311.924% |